The BALANCE Model, GLP-1 Coverage, and the Peptide Regulatory Collision: What Every Health Tech Operator and Investor Needs to Know Right Now
Abstract
CMS launched the BALANCE Model in December 2025, a 1115A Innovation Center voluntary model that for the first time waives the Part D statutory exclusion on weight loss drugs, negotiating net prices of $245/month for Zepbound and model drugs from Novo Nordisk (Ozempic, Rybelsus, Wegovy) and Eli Lilly (Mounjaro, Zepbound, and pending FDA approval, orforglipron)
The Part D application deadline is April 20, 2026, with an 80% beneficiary participation threshold that CMS will evaluate by April 30, 2026 to determine whether the model launches in Medicare in January 2027
A Medicare GLP-1 Bridge demonstration launches July 2026 at $50/month copay, operating entirely outside the Part D benefit structure, meaning plans carry zero risk
Medicaid states can join on a rolling basis from May 2026 through January 2027, executing supplemental rebate agreements that reflect CMS-negotiated key terms
Simultaneously, FDA peptide regulation is in upheaval: semaglutide and tirzepatide were removed from the drug shortage list in early 2025, HHS Secretary Kennedy announced in February 2026 that ~14 of 19 restricted Category 2 peptides would return to Category 1 compounding status, and the formal reclassification publication remains pending
The convergence of BALANCE’s government-negotiated GLP-1 pricing with FDA’s peptide compounding crackdown and subsequent partial reversal creates a complex opportunity map for providers, pharmacies, manufacturers, wellness companies, d2c telehealth, payers, entrepreneurs, and investors
Table of Contents
What BALANCE Actually Is (and What It Isnt)
The Mechanics: Pricing, Rebates, and the Facilitated DIR Field
Part D Plan Sponsors: The 80% Threshold Problem
Medicaid: The Rolling On-Ramp
The Bridge Demo: Why July 2026 Matters More Than January 2027
Provider Strategy: PA Criteria, Auto-Lookback, and Patient Volume
Pharmacy and PBM Implications
Pharma Manufacturers: Lilly and Novo in a Negotiated Cage
Wellness Companies and Lifestyle Support: The Mandated Wraparound
D2C Telehealth: The Compounding Cliff Meets Government Pricing
FDA Peptide Activity: The Category 2 to Category 1 Reversal
Payer Strategy: Risk Corridors, Adverse Selection, and Bid Uncertainty
The Entrepreneur and Investor Lens
What BALANCE Actually Is (and What It Isnt)
The BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, because government acronyms gonna government acronym) is a CMMI 1115A demonstration. That statutory authority matters. It means CMS can waive provisions of the Social Security Act to test payment and delivery models. In this case the single most consequential waiver is of Section 1860D-2(e), which has historically excluded drugs used for weight loss from Part D coverage. That exclusion has been the law since 2003. Twenty-plus years of Part D and weight loss drugs have never been covered. BALANCE changes that for participating plans.
But it is voluntary. Manufacturers, states, and Part D sponsors all opt in. The model runs January 2027 through December 2031 for Part D, with Medicaid states joining on a rolling window from May 2026 through January 2027. CMS negotiated directly with Eli Lilly and Novo Nordisk during a pre-implementation period from January 12 through February 5, 2026, and those manufacturers executed Participation Agreements by February 28, 2026. The negotiated drugs include all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy, the KwikPen formulation of Zepbound, and orforglipron tablets if FDA approves them. The net price for Zepbound is $245 per month supply. Novo’s pricing for its portfolio is listed in the RFA appendix but follows similar negotiated terms.
What BALANCE is not: it is not a permanent statutory change. It is not the IRA’s Medicare Drug Price Negotiation Program, although it interacts with it in weird ways (more on that below). It is not a guarantee of coverage for any individual patient. And it absolutely is not universal, because if fewer than 80% of Part D beneficiaries are enrolled in participating plans, the whole Medicare side does not launch.
The Mechanics: Pricing, Rebates, and the Facilitated DIR Field
The payment plumbing here is genuinely interesting and worth understanding because it tells you where the money flows. CMS negotiated a net price with manufacturers. That net price includes all discounts, rebates, and price concessions. For drugs that are also selected under the IRA’s Negotiation Program (which applies to some of these products), CMS is waiving the Maximum Fair Price requirement. Instead, plans will use WAC as the base for gross drug cost calculations, and manufacturers will pay rebates through a new PDE field called Facilitated DIR (FAD).
The FAD field calculates the difference between the ingredient cost the plan reports on the PDE and the sum of the GLP-1 Discounted Price plus the Manufacturer Discount Program amount. Manufacturers get invoiced quarterly through the existing MDP portal with separate model-specific invoices. Plans do not report the FAD amount on the DIR Report for Payment Reconciliation, but CMS incorporates it into annual reconciliation.
Why does this matter? Because it means plans are not chasing manufacturers for rebates. CMS is intermediating the rebate flow, which dramatically reduces administrative friction for plans. It also means CMS has real-time visibility into whether plans are complying with price guidance, and it protects beneficiary and physician data by keeping the invoicing process clean on the CMS side rather than requiring plans to share utilization data directly with manufacturers.
There is a 340B adjustment baked in too. Rebates get reduced by up to 5% to account for the fact that manufacturers will be paying model rebates on units purchased by 340B covered entities at already-discounted prices. This is a small but important detail for health systems running 340B programs who are evaluating the model.
Part D Plan Sponsors: The 80% Threshold Problem
This is the single most important near-term question in the entire model. CMS requires that plans representing at least 80% of NAMBA-eligible beneficiaries apply to participate. If they do not hit that number, BALANCE does not launch in Medicare in 2027. Period. CMS calculates the threshold based on February 2026 enrollment data, projected forward. The denominator includes all NAMBA-eligible plan types plus Defined Standard plans (even though DS plans cannot actually participate). The numerator is beneficiaries in plans that applied. SNPs and EGWPs are excluded from the calculation even though they can participate.
The application deadline was April 20, 2026. CMS targets April 30, 2026 to notify plans whether the threshold was met. As of this writing, that notification should be imminent or already out. If it cleared, the next milestone is June 1, 2026, when plans indicate participation in HPMS and submit bids reflecting BALANCE. Contract addendums execute in September 2026.
Participation is at the parent organization level, which is a big deal. A parent org must include all of its Enhanced Alternative plans. It must also include 90% of beneficiary enrollment in its basic plans (excluding ineligible types and DS plans). DS plans cannot participate because they cannot offer the reduced cost sharing while maintaining DS status, but parent orgs can convert DS plans to BA or AE benefit types for 2027. EGWPs can participate but are not required to.
For plans, the decision tree is: if enough of the market applies, you are probably going to have to participate because not participating means your competitors offer $50 or $125 copay GLP-1s and you do not. The adverse selection concern is real (people who want GLP-1s will shop for plans that cover them) and that is exactly why CMS set the 80% threshold so high. If basically everyone is in, adverse selection washes out.
Medicaid: The Rolling On-Ramp
The Medicaid side works differently. States apply through a Qualtrics link by July 31, 2026, execute State Agreements with CMS by January 1, 2027, and enter supplemental rebate agreements with each participating manufacturer. States that need SPAs or new state legislation can work with CMCS to get those in place. States can start as early as May 2026 with just FFS populations and bring managed care populations in later, as long as everything is live by January 1, 2027.
The coverage criteria are identical to the Part D criteria (same BMI thresholds, same comorbidity requirements), and the Medicaid Key Terms are standardized. States can vary terms with CMS approval but cannot disadvantage one model drug relative to another. Managed care plans within participating states must apply the same access policy as FFS.
For investors watching the Medicaid managed care space, this matters because MCOs in participating states will need to cover these drugs at negotiated prices with standardized PA criteria. That is new cost exposure but also new opportunity if the drugs reduce downstream utilization of hospitalizations, ER visits, and specialty care. The question of whether GLP-1s are net savings or net cost for Medicaid populations is going to be the subject of the model evaluation, but anyone who has been following the cardiovascular outcomes data from SELECT and STEP-HFpEF trials knows the clinical signal is strong.
The Bridge Demo: Why July 2026 Matters More Than January 2027
Before BALANCE even launches, CMS is running a separate Medicare GLP-1 payment demonstration starting July 2026. This is often overlooked but it is arguably the bigger near-term catalyst. The bridge demo operates entirely outside the Part D benefit’s coverage and payment flow. Part D sponsors carry zero risk. CMS uses a single central processor to manage prior authorization, claims adjudication, and payment to pharmacies. Eligible beneficiaries pay $50 per month for Wegovy or Zepbound.
This means that starting mid-2026, millions of Medicare Part D beneficiaries can access GLP-1s for weight management at $50/month regardless of what their plan does. The catch: it ends December 31, 2026. So beneficiaries who start on the bridge need to enroll in a BALANCE-participating plan for 2027 to maintain access. CMS has said they will do beneficiary outreach and education around this transition.
From a market dynamics perspective, the bridge demo is going to create a massive cohort of Medicare patients on GLP-1s before BALANCE launches. That is demand that gets locked in. Plans that do not participate in BALANCE will lose those members during open enrollment. This is the stick that makes the 80% threshold achievable.
Provider Strategy: PA Criteria, Auto-Lookback, and Patient Volume
The prior authorization criteria under BALANCE are more generous than many expected. The three tiers are: (1) BMI 35 or above with lifestyle modification, (2) BMI 30 or above with specific comorbidities like HFpEF, uncontrolled hypertension, CKD stage 3a+, moderate/severe OSA, or noncirrhotic MASH F2-F3, and (3) BMI 27 or above with pre-diabetes, previous MI, previous stroke, or symptomatic PAD. Patients with type 2 diabetes, MASH with F2-F3 fibrosis, or OSA do not even need to meet a BMI threshold for the lifestyle modification pathway.
The Auto-Lookback provision is really interesting for health IT companies. Plans are directed to try to confirm PA through automated review of patient health records via ICD-10 code matching before requiring provider attestation. If the automated check fails, then provider attestation is sufficient. This creates an opportunity for companies building prior authorization automation, clinical data matching, and interoperability tooling. The plans that execute Auto-Lookback well will have lower administrative costs and faster patient access.
For provider organizations, the volume implications are significant. CMS is essentially telling every primary care doc in America that their Medicare patients with BMI 30+ and common comorbidities can now get GLP-1s covered. The prescribing volume is going to be enormous. Practices need to think about PA workflow capacity, patient education at scale, and monitoring protocols. Obesity medicine as a specialty is about to see a massive demand surge.
Pharmacy and PBM Implications
Participating plans must reimburse in-network pharmacies at no less than WAC plus sales tax plus a dispensing fee. That WAC-plus floor is a real win for pharmacies that were worried about being squeezed. Mail order and specialty pharmacy are both eligible channels. The cost sharing maximums ($50 for EA/EGWP plans, $125 for AE/BA plans) apply at all in-network pharmacy types, preferred and non-preferred, retail and mail.
For PBMs, the FAD field changes rebate economics. PBMs typically negotiate and retain a share of DIR rebates. Under BALANCE, the manufacturer rebates flow through CMS’s invoicing system, not through PBM-negotiated contracts. PBMs will need to figure out how model drugs interact with their existing rebate structures for non-model indications and non-model plans. This is a structural change to the PBM value proposition for this drug class.
Community pharmacies should be paying close attention to the bridge demo’s central processor model. If CMS builds an effective centralized claims processing system for the bridge, that infrastructure could influence future payment models beyond GLP-1s.
Pharma Manufacturers: Lilly and Novo in a Negotiated Cage
Eli Lilly and Novo Nordisk both signed Participation Agreements. They accepted $245/month net pricing (for Zepbound at least, and comparable pricing for Novo products). That is roughly 75-80% off WAC depending on the specific product. In exchange they get access to the entire Medicare and Medicaid population at negotiated volume with standardized coverage criteria.
The manufacturers are also required to fund lifestyle support programs at no cost to plans or beneficiaries. These programs must cover diet and nutrition counseling, physical activity support, medication adherence tools, and must be delivered on a recurring basis with accessibility accommodations for patients with limited digital access. The safe harbor at 42 CFR 1001.952(ii) protects manufacturers from anti-kickback exposure on these programs, but only within the model.
For Lilly specifically, orforglipron is the sleeper hit. If FDA approves the oral GIP/GLP-1 receptor agonist, it enters the model immediately. An oral formulation at $245/month with Medicare and Medicaid coverage would be enormously disruptive to the injectable-dominated market. Lilly filed the NDCs in the RFA appendix, which suggests they are confident on approval timing.
Wellness Companies and Lifestyle Support: The Mandated Wraparound
The lifestyle support mandate is where wellness, digital health, and coaching companies should be paying very close attention. Manufacturers are on the hook to provide these programs, but the RFA language around program requirements reads like a digital health company’s product spec sheet: diet and nutrition with GI side effect management, physical activity promotion, medication adherence with reminders and injection site guidance, recurrent engagement with weight logging and goal review, and scalable delivery including offline options for patients without digital access.
Lilly and Novo are going to need partners to deliver this at the scale of the Medicare and Medicaid population. They are not going to build this in-house. That means contracts for digital health platforms, health coaching companies, nutrition counseling services, and patient engagement technology. If you are building in the GLP-1 support ecosystem (think Noom, Calibrate-style models, clinical coaching platforms, remote patient monitoring for metabolic health), the manufacturer lifestyle support mandate just created a guaranteed buyer.
CMS has also said it expects to revisit lifestyle support requirements annually and may shift responsibility to states and MA-PD plans in future years. That is a signal that this could evolve from a manufacturer-funded mandate to a plan-funded benefit, which would further expand the addressable market for wellness and coaching companies.
D2C Telehealth: The Compounding Cliff Meets Government Pricing
This is where things get really spicy. The d2c telehealth GLP-1 market has been built on two pillars: compounded semaglutide at $200-400/month, and the ability to prescribe without the friction of traditional insurance PA. BALANCE and the FDA’s regulatory actions are attacking both pillars simultaneously.
On the compounding side, FDA removed semaglutide from the drug shortage list in February 2025 and tirzepatide in October 2024. The legal basis for shortage-based 503B compounding effectively evaporated, though ongoing litigation and 503A patient-specific compounding have kept some supply flowing. As of April 2026, the landscape is messy: 503A compounding continues under physician prescription, many 503B facilities are operating under court injunctions or enforcement uncertainty, and the gray market is still active.
Meanwhile, BALANCE introduces branded GLP-1s at $50/month copay for Medicare EA/EGWP plans and through the bridge demo. Even the $125/month AE/BA copay is competitive with compounded pricing. For Medicaid populations, cost sharing will be even lower. This fundamentally changes the value proposition for d2c telehealth companies selling compounded GLP-1s to commercially insured or cash-pay patients, because the comparison anchor just dropped from $1,000+/month brand name to $50-245/month government-negotiated.
Companies like Hims and Hers, Ro, and the dozens of smaller d2c GLP-1 telehealth plays need to be thinking about what their business looks like when the government is offering branded Wegovy at $50/month. The cash-pay compounded model only works if it is cheaper or more accessible than the covered option. For Medicare and Medicaid patients, that calculus just shifted dramatically. For commercially insured patients, the BALANCE pricing will create employer and plan pressure to match.
FDA Peptide Activity: The Category 2 to Category 1 Reversal
Running in parallel with BALANCE is a wild chapter in FDA peptide regulation. In September 2023, FDA placed 19 commonly used peptides on the Category 2 restricted list, effectively banning compounding pharmacies from preparing them. This included BPC-157, Thymosin Alpha-1, TB-500, CJC-1295/Ipamorelin, AOD-9604, and others widely used in wellness and longevity medicine.
Then in February 2026, HHS Secretary Kennedy announced on the Joe Rogan podcast (yes, really) that approximately 14 of the 19 would be reclassified back to Category 1, restoring legal compounding access under physician prescription. The five expected to stay restricted include Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF. As of early April 2026, the formal FDA publication has not been released, so compounding pharmacies technically cannot resume production yet.
The connection to BALANCE is not immediately obvious but it matters for understanding the broader regulatory picture around peptide therapeutics in government health programs. GLP-1 receptor agonists like semaglutide and tirzepatide are themselves peptides. They are fully FDA-approved peptide drugs. The compounding crackdown on GLP-1s (shortage list removal, enforcement actions against compounders, Lilly and Novo litigation against clinics) and the partial reversal on non-GLP-1 peptides reflect two different regulatory postures for two different categories of peptide products.
For the investment thesis, the regulatory bifurcation creates distinct lanes. FDA-approved GLP-1 peptides are moving toward government-negotiated pricing and broad coverage through BALANCE. Non-approved peptides used in wellness and longevity are moving toward restored compounding access under physician supervision, but without insurance coverage and with ongoing quality concerns. These are fundamentally different market structures and business models, and conflating them is a mistake a lot of generalist investors make.
Payer Strategy: Risk Corridors, Adverse Selection, and Bid Uncertainty
The risk corridor modification is a clever incentive that deserves more attention. Under standard Part D, the first risk corridor threshold is plus or minus 5% of the target amount, with plans bearing 100% of the variance within that band. BALANCE offers an optional narrowed first threshold of plus or minus 2.5% for plans that opt in and subsequently experience model drug utilization more than one standard deviation above the mean for their plan type.
The mechanics are retrospective: CMS calculates utilization rates after the plan year, compares them to the mean and standard deviation across all eligible participating plans of the same type, and narrows the corridor for plans that got hit hardest. This is essentially CMS saying “if you get adverse selection, we will share the risk.” It is available for the first two years of the model, with potential extension based on results.
For payer actuaries, the bid uncertainty is the real challenge. Plans need to submit CY 2027 bids in June 2026 reflecting BALANCE participation. They are pricing a new drug class that has never been in the Part D benefit. They do not know what utilization will look like. They do not know how many of their members will meet the PA criteria. The narrowed risk corridor helps, but the first year is going to be a massive exercise in actuarial estimation with limited data. Plans with better analytics capabilities, especially those that can model the intersection of their current membership demographics, chronic condition prevalence, and the specific PA criteria, will have a meaningful advantage in bid accuracy.
The Entrepreneur and Investor Lens
So where does all of this leave entrepreneurs building companies and investors deploying capital in health tech?
First, the obvious: anything that reduces friction in the GLP-1 prescribing and monitoring workflow for participating plans and providers is going to see demand. PA automation that can handle the BALANCE-specific criteria and auto-lookback ICD-10 matching. Clinical decision support that helps PCPs identify eligible patients in their panel. Remote monitoring and coaching platforms that can serve the lifestyle support mandate. Lab ordering and metabolic health monitoring tooling. All of these are immediate build opportunities.
Second, the less obvious: BALANCE creates a data exhaust that will be extremely valuable. CMS is going to collect PDE data, utilization data, clinical outcomes data, and patient-reported measures across the entire model population over five years. Companies that position to help CMS, plans, states, or manufacturers analyze this data, reconcile rebates, monitor quality metrics, or support evaluation activities will find willing buyers. The FAD field alone creates a new data infrastructure requirement for every participating plan.
Third, the competitive dynamics in d2c telehealth are about to shift hard. Companies built on compounded GLP-1 margin are going to need to pivot toward branded drug access facilitation, comprehensive metabolic health management, or differentiated clinical services that justify their existence in a world where Medicare patients can get Wegovy for $50. The companies that survive this transition will be the ones that were always more than a pharmacy arbitrage play.
Fourth, the wellness and lifestyle support space just got a government-mandated TAM expansion. Manufacturers need to procure these services at scale. Plans may need to procure them in future model years. The specification in the RFA (diet/nutrition, physical activity, medication adherence, recurrence, scale/accessibility) reads like a product requirements doc. Companies that can deliver evidence-based lifestyle interventions at Medicare-and-Medicaid scale, including offline delivery for digitally underserved populations, have a clear path to contracted revenue.
Fifth, and this is the longer-term play, watch what happens with orforglipron. If Lilly gets FDA approval for an oral GLP-1 that enters the model at $245/month, the entire delivery model changes. No more cold chain. No more injection training. No more specialty pharmacy gatekeeping. Oral administration at government-negotiated prices is a completely different product from injectable semaglutide at $1,300/month. The downstream effects on patient adherence, prescriber behavior, pharmacy logistics, and competitive positioning are going to be massive.
On the peptide side, the Category 2 to Category 1 reversal creates a separate but parallel opportunity in wellness and longevity medicine. BPC-157, Thymosin Alpha-1, and the other returning peptides will flow through compounding pharmacies under physician prescription, serving a cash-pay, wellness-oriented population that is largely distinct from the BALANCE population. Companies building peptide therapy platforms, compounding pharmacy networks, or clinical protocols for non-GLP-1 peptides should be scaling their physician networks and pharmacy relationships now, ahead of the formal FDA reclassification publication.
The macro picture is that the federal government just decided to become the single largest purchaser of GLP-1s in the world, at prices 75-80% below list, with mandatory lifestyle support and standardized coverage criteria, across both Medicare and Medicaid. At the same time, FDA is unwinding its most aggressive compounding restrictions on non-GLP-1 peptides while maintaining pressure on compounded GLP-1s. These two regulatory vectors create very different market structures for very different patient populations, and the companies and investors that understand the distinction clearly will be positioned to capture the most value. The ones who treat “peptides” as a monolithic category or who assume the compounding arbitrage window stays open forever are going to get caught.
The next 90 days are going to tell the story. The 80% participation threshold decision. The bridge demo operational guidance. The FDA formal peptide reclassification publication. State Medicaid applications rolling in. Any one of these could reshape assumptions. Keep close to the primary source documents, read the RFAs yourself, and do not rely on secondary coverage that smooths over the details. The details are where the alpha is.
